Alexion touts early 'proof-of-concept' data for Neurimmune antibody in ATTR cardiomyopathy
Alexion and its partners at Neurimmune have offered a first look into their Phase I candidate for transthyretin amyloid cardiomyopathy, touting early biomarker data that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
